Biogen Idec, Elan Plummet On Withdrawal Of Tysabri
Two serious adverse events - one ending in death - was enough for Biogen Idec Inc. and Elan Corp. plc to suspend marketing of their multiple sclerosis drug, Tysabri, just three months after FDA approval.